News Releases

Hiring of the US sales force is 97% complete and sales training has commenced 14 Key Opinion Leader (KOL) speakers have been identified and speaker training has commenced Two-pronged market access and reimbursement strategy has commenced CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.

Peter K Honig, MD, MPH and Michael A.S. Jewett , MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company

Anticipated submission of product market application for Vicineum in China in 2022, with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of

No Advisory Committee meeting is planned at this time No confirmatory trial required at this time Company believes it remains on track for August 18 th target PDUFA date CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 14, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the

Technology transfer to Qilu Pharmaceutical on track for completion in 2021 Sesen Bio to receive $2M milestone payment upon completion of technology transfer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein

Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 27, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Sesen Bio President and CEO Dr.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the